Combined pharmacological therapy of the acute radiation disease using a cyclooxygenase-2 inhibitor and an adenosine A3 receptor agonist

Central European Journal of Biology

Volumn 9, Issue 6, 2014, Pages 642-646

  Hofer, Michal ^a   Pospíšil, Milan ^a   Dušek, Ladislav ^b   Hoferová, Zuzana ^a   Komůrková, Denisa ^a  

^a INSTITUTE OF BIOPHYSICS   (Czech Republic)

^b MASARYK UNIVERSITY   (Czech Republic)

Author keywords

Adenosine receptor agonist; Cyclooxygenase inhibition; Hematopoiesis; Post radiation pharmacological approach; Radiation induced myelosuppression

Indexed keywords

EID: 84896934898     PISSN: 1895104X     EISSN: 16443632     Source Type: Journal    
DOI: 10.2478/s11535-014-0295-0     Document Type: Review

References (36)

1. Weiss J. F., Kumar K. S., Walden T. L., Neta R., Landauer M. R., Clark E. P., Advances in radioprotection through the use of combined agent regimen, Int. J. Radiat. Biol., 1990, 57, 709-722.
2. Stone, H. B., McBride W. H., Coleman C. N., Modifying normal tissue damage postirradiation. Report of a workshop sponsored by the Radiation Research Program, National Cancer Institute, Bethesda, Maryland, September 6-8, 2000. Radiat. Res., 2002, 157, 204-223.
3. Moulder J. E., Post-irradiation approaches to treatment of radiation injuries in the context of radiological terrorism and radiation accidents: a review. Int. J. Radiat. Biol., 2004, 80, 3-10.
4. Waselenko J. K., MacVittie T. J., Blakely W. F., Pesik N., Wiley A. L., Dickerson W. E., et al., Medical management of the acute radiation syndrome: Recommendations of the Strategic National Stockpile Radiation Working Group. Ann. Intern. Med., 2004, 140, 1037-1051.
5. Gourmelon P., Benderitter M., Bertho J. M., Huet C., Gorin N. C., De Revel P., European consensus on the medical management of acute radiation syndrome and analysis of the radiation accidents in Belgium and Senegal, Health Phys., 2010, 98, 825-832.
6. Ross J. R., Case C., Confer D., Weisdorf J., Weinstock D., Krawisz R., et al., Radiation Injury Treatment Network (RITN): Healthcare professionals preparing for a mass casualty radiological or nuclear accidents, Int. J. Radiat. Biol., 2011, 87, 748-753.
7. Pellmar T. C., Rockwell S., and the Radiological/Nuclear Threat Countermeasures Working Group, Priority list of research areas for radiological nuclear threat countermeasures, Radiat. Res., 2005, 163, 115-123.
8. Frölich J. C., A classification of NSAIDs according to the relative inhibition of cyclooxygenase isoenzymes, Trends Pharmacol. Sci., 1997, 18, 30-34.
9. Simmons D. L., Botting R. M., Hla T., Cyclooxygenase isoenzymes: The biology of prostaglandin synthesis and inhibition, Pharmacol. Rev., 2004, 56, 387-437.
10. Smith W. L., Urade Y., Jakobsson P.-J., Enzymes of the cyclooxygenase pathways of prostanoid synthesis, Chem. Rev., 2011, 111, 5821-5865.
11. Gentile P., Byer D., Pelus L. M., In vivo modulation of murine myelopoiesis by intravenous administration of prostaglandin E2, Blood, 1983, 62, 1100-1107.
12. Pelus L. M., Modulation of myelopoiesis by prostaglandin E2: Demonstration of a novel mechanism of action in vivo, Immunol. Res., 1989, 8, 176-184.
13. Hofer M., Pospíšil M., Stimulated recovery of perturbed haematopoisis by inhibition of prostaglandin production - promising therapeutic strategy, Cent. Eur. J. Biol. 2006, 1, 584-593.
14. Hofer M., Pospíšil M., Tkadleček L., Viklická Š., Pipalová I., Low survival of mice following lethal gamma-irradiation after administration of inhibitors of prostaglandin synthesis, Physiol. Res., 1992, 41, 157-161.
15. Hofer M., Pospíšil M., Hoferová Z., Weiterová L., Komůrková D., Stimulatory action of cyclooxygenase inhibitors on hematopoiesis: A review, Molecules, 2012, 17, 5615-5625.
16. Hoggatt J., Singh P., Stilger K. N., Plett P. A., Sampson C. H., Orschell C. M., et al., Recovery from hematopoietic injury by modulating prostaglandin E2 signaling post-irradiation. Blood Cells Mol. Dis., 2013, 50, 147-153.
17. Linden J., Molecular approach to adenosine receptors: Receptor-mediated mechanisms of tissue protection, Annu. Rev. Pharmacol. Toxicol., 2001, 41, 775-778.
18. Poulsen S.-A., Quinn R. J., Adenosine receptors: New opportunities for future drugs, Bioorgan. Med. Chem., 1998, 6, 619-641.
19. Klotz K.-N., Adenosine receptors and their ligands, Naunyn-Schmied. Arch. Pharmacol., 2000, 362, 382-391.
20. Hofer M., Pospíšil M., Netíková J., Znojil V., Vácha J., Granulocyte colony-stimulating factor and drugs elevating extracellular adenosine act additively to enhance the hemopoietic spleen colony formation in irradiated mice, Physiol. Res., 1999, 48, 37-42.
21. Hofer M., Pospíšil M., Role of adenosine signaling in hematopoiesis - A short review, Med. Hypotheses Res., 2006, 3, 629-635.
22. Hofer M., Pospisil M., Weiterova L., Hoferova Z., The role of adenosine receptor agonists in regulation of hematopoiesis, Molecules, 2011, 16, 675-685.
23. Hofer M., Pospíšil M., Znojil V., Holá J., Vacek A., Štreitová D., Meloxicam, an inhibitor of cyclooxygenase-2, increases the level of serum G-CSF and might be suitable as an auxiliary means in G-CSF therapy, Physiol. Res., 2008, 57, 307-310.
24. Hofer M., Pospíšil M., Holá J., Vacek A., Štreitová D., Znojil V., Inhibition of cyclooxygenase 2 in mice increases production of G-CSF and induces radioprotection, Radiat. Res., 2008, 170, 566-571.
25. Hofer M., Pospíšil M., Šefc L., Dušek L., Vacek A., Holá J., et al., Activation of adenosine A3 receptors supports hematopoiesis-stimulating effects of granulocyte colony-stimulating factor in sublethally irradiated mice, Int. J. Radiat. Biol., 2010, 86, 649-656.
26. Bar-Yehuda S., Madi L., Barak D., Mittelman M., Ardon E., Ochaion A., et al., Agonists to the A3 adenosine receptor induce G-CSF peroduction via NF-κB activation: A new class of myeloprotective agents, Exp. Hematol., 2002, 30, 1390-1398.
27. Hofer M., Pospíšil M., Dušek L., Hoferová Z., Weiterová L., Inhibition of cyclooxygenase-2 promotes the stimulatory action of adenosine A3 receptor agonist in sublethally γ-irradiated mice, Biomed. Pharmacother., 2011, 65, 427-431.
28. Hofer M., Pospíšil M., Dušek L., Hoferová Z., Komůrková D., Agonist of the adenosine A3 receptor, IB-MECA, and inhibitor of cyclooxygenase-2, meloxicam, given alone or in a combination early after total body irradiation enhance survival of Γ-irradiated mice, Radiat. Environ. Biophys., 2014, 53, 211-215.
29. Farese A. M., Hunt P, Grab L. B., MacVittie T. J., Combined administration of recombinant human megakaryocyte growth and development factor and granulocyte colony-stimulating factor enhances multilineage hematopoietic reconstitution in nonhuman primates after radiation-induced marrow aplasia, J. Clin. Invest., 1996, 97, 2145-2151.
30. Drouet M., Delaunay C., Grenier N., Garrigou P., Mayol J. F., Hérodin F., Cytokines in combination to treat radiation-induced myelosuppression: Evaluation of SCF + glycosylated EPO + pegylated G-CSF as an emergency treatment in highly irradiated monkeys, Haematologica, 2008, 93, 465-466.
31. Hérodin F., Bourin P., Mayol J. F., Lataillade J. J., Drouet M., Short-term injection of antiapoptotic cytokine combinations soon after lethal γ-irradiation promotes survival, Blood, 2003, 101, 2609-2616.
32. Hérodin F., Drouet M., Cytokine-based treatment of accidentally irradiated victims and new approaches, Exp. Hematol., 2005, 33, 1071-1080.
33. Hérodin F., Drouet M., Myeloprotection following cytotoxic damage: The sooner, the better, Exp. Hematol., 2008, 36, 769-770.
34. Silverman M. H., Strand V., Markovits D., Nahir M., Reitblat T., Molad Y., et al., Clinical evidence for utilization of the A3 adenosine receptor as a target to treat rheumatoid arthritis: Data from a phase II clinical trial, J. Rheumatol., 2008, 35, 41-48.
35. David M., Akerman L., Ziv M., Kadurina M., Gospodinov D., Pavlotsky F., et al., Treatment of plaque-type psoriasis with oral CF101: data from an exploratory randomized phase 2 clinical trial, J. Eur. Acad. Dermatol. Venereol., 2012, 26, 361-367.
36. Fishman P., Cohen S., Bar-Yehuda S., Targeting the A3 adenosine receptor for glaucoma treatment (Review), Mol. Med. Rep., 2013, 7, 1723-1725.